Skip to main content

and
  1. Article

    Publisher Correction: Autophagy promotes growth of tumors with high mutational burden by inhibiting a T-cell immune response

    Laura Poillet-Perez, Daniel W. Sharp, Yang Yang, Saurabh V. Laddha in Nature Cancer (2021)

  2. No Access

    Article

    Autophagy promotes growth of tumors with high mutational burden by inhibiting a T-cell immune response

    Macroautophagy (hereafter autophagy) degrades and recycles intracellular components to sustain metabolism and survival during starvation. Host autophagy promotes tumor growth by providing essential tumor nutri...

    Laura Poillet-Perez, Daniel W. Sharp, Yang Yang, Saurabh V. Laddha in Nature Cancer (2020)

  3. No Access

    Article

    Phase I neoadjuvant study of intravesical recombinant fowlpox-GM-CSF (rF-GM-CSF) or fowlpox-TRICOM (rF-TRICOM) in patients with bladder carcinoma

    Intravesical BCG is a highly effective treatment for high-grade nonmuscle invasive bladder cancer and carcinoma in situ (CIS); however, for patients who are either resistant or become unresponsive to BCG thera...

    Daniella E. Portal, Robert E. Weiss, Malgorzata Wojtowicz in Cancer Gene Therapy (2020)

  4. No Access

    Article

    Virotherapy clinical trials for regional disease: In situ immune modulation using recombinant poxvirus vectors

    The ability of viruses to readily infect tumor cells both in vitro and in vivo has resulted in their study as antitumor agents through a variety of strategies. Replicating and conditionally replicating viruses an...

    Michael J Mastrangelo, Edmund C Lattime in Cancer Gene Therapy (2002)

  5. No Access

    Chapter

    Intralesional Vaccinia/GM-CSF Recombinant Virus in the Treatment of Metastatic Melanoma

    Michael J. Mastrangelo, Henry C. Maguire, Edmund C. Lattime in Cancer Gene Therapy (2002)

  6. No Access

    Article

    Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma

    Seven immunocompetent, revaccinated patients with surgically incurable cutaneous melanoma underwent treatment of dermal and/or subcutaneous metastases with twice-weekly intratumoral injections of escalating do...

    Michael J Mastrangelo, Henry C Maguire Jr., Laurence C Eisenlohr in Cancer Gene Therapy (1999)

  7. No Access

    Chapter

    Cellular vaccine therapies for cancer

    The presence of functionally specific tumor-associated antigens was first convincingly demonstrated by Prehn and Main [1]. These investigators immunized syngeneic mice with a chemically induced sarcoma using a te...

    Michael J. Mastrangelo, Takami Sato in Biological and Hormonal Therapies of Cancer (1998)

  8. No Access

    Article

    Expression of cytokine mRNA in human melanoma tissues

    We have reported that patients with metastatic melanoma treated with an autologous, dinitrophenol-modified vaccine develop inflammatory responses at tumor sites. Histologically, these inflamed lesions are char...

    Edmund C. Lattime, Michael J. Mastrangelo, Omar Bagasra in Cancer Immunology, Immunotherapy (1995)

  9. No Access

    Article

    Induction of TH1- and TH2-associated cytokine mRNA in mouse bladder following intravesical growth of the murine bladder tumor MB49 and BCG immunotherapy

    Productive immunity to murine and human parasites is associated with the development of a type I T cell response (interferon-γ-producing) while type II responses (interleukin-4-producing) suppress the developm...

    Kathleen M. McAveney, Leonard G. Gomella in Cancer Immunology, Immunotherapy (1994)

  10. No Access

    Article

    Natural cytotoxic (NC) activity: A multi-lineage system regulated by IL-2

    The studies described in this report demonstrate that NC activity is the function of a number of distinct effector cell populations and not due to a single type of NC cell. While IL-2 was found to augment the ...

    Edmund C. Lattime, Michael J. Bykowsky, Osias Stutman in Immunologic Research (1986)

  11. No Access

    Article

    Natural cytotoxic activity: An introduction

    Edmund C. Lattime in Immunologic Research (1986)